Radiotherapy and Oncology最新文献

筛选
英文 中文
Randomized trials: When scientific rigor meets field reality 随机试验:当科学严谨遇到实地现实。
IF 4.9 1区 医学
Radiotherapy and Oncology Pub Date : 2025-02-01 DOI: 10.1016/j.radonc.2024.110659
J.M. Hannoun-Levi , A. Savignoni , J. Lemonnier , Youlia Kirova
{"title":"Randomized trials: When scientific rigor meets field reality","authors":"J.M. Hannoun-Levi ,&nbsp;A. Savignoni ,&nbsp;J. Lemonnier ,&nbsp;Youlia Kirova","doi":"10.1016/j.radonc.2024.110659","DOIUrl":"10.1016/j.radonc.2024.110659","url":null,"abstract":"<div><div>Results from prospective randomized trial results are required to provide practice-changing level-1 evidence. However, if such a trial is not feasible, we should not accept that consequently practice could not change. We discuss hereby a pragmatically approach based on methodological alternatives.</div></div>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":"203 ","pages":"Article 110659"},"PeriodicalIF":4.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142791775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Routine review of patient-reported outcome data influences radiotherapy care: IMPROVE study results 患者报告的结果数据影响放射治疗的常规回顾:改善研究结果。
IF 4.9 1区 医学
Radiotherapy and Oncology Pub Date : 2025-02-01 DOI: 10.1016/j.radonc.2024.110688
Khinh Ranh Voong , Siyao Li , Chen Hu , Ori Shokek , Russell K. Hales , Jeffrey Meyer , Stephen Greco , Todd McNutt , Colin Hill , Kathryn Lowe , James Huang , Jean Wright , Amol Narang , Aditya Halthore , Andrea Brown , Shing Lee , Claire Snyder
{"title":"Routine review of patient-reported outcome data influences radiotherapy care: IMPROVE study results","authors":"Khinh Ranh Voong ,&nbsp;Siyao Li ,&nbsp;Chen Hu ,&nbsp;Ori Shokek ,&nbsp;Russell K. Hales ,&nbsp;Jeffrey Meyer ,&nbsp;Stephen Greco ,&nbsp;Todd McNutt ,&nbsp;Colin Hill ,&nbsp;Kathryn Lowe ,&nbsp;James Huang ,&nbsp;Jean Wright ,&nbsp;Amol Narang ,&nbsp;Aditya Halthore ,&nbsp;Andrea Brown ,&nbsp;Shing Lee ,&nbsp;Claire Snyder","doi":"10.1016/j.radonc.2024.110688","DOIUrl":"10.1016/j.radonc.2024.110688","url":null,"abstract":"<div><h3>Background</h3><div>Radiation oncologists closely monitor patients during weekly on-treatment visits (OTVs). This study examines whether routine patient-reported outcome measures (PROMs) during OTVs change physicians’ perceptions of treatment-toxicity and inform symptom-management.</div></div><div><h3>Patient and methods</h3><div>IMPROVE is a single-arm prospective multicenter trial, conducted from 2020 to 2023. Patients with locally-advanced or oligometastatic thoracic or gastrointestinal cancers receiving definitive-intent radiation, with or without chemotherapy, and their physicians enrolled. Patients completed a 14-question disease-specific PROM in clinic prior to OTVs. Physicians rated their patient’s global toxicity-burden based on clinical data/assessments, then re-rated their patient’s toxicity-burden and reported management-changes after PROM review. At radiotherapy end, physicians completed a Feedback Form. PROMs and outcome-data collection used electronic or paper forms. We report any change in physician-assessed burden-score and symptom-management due to PROMs.</div></div><div><h3>Results</h3><div>The 100 patients enrolled (49 academic, 51 community-based) were 70 years old (median), 51% female, 81% Caucasian, 95% ECOG 0-1, and 94% received concurrent chemotherapy. The median radiation dose was 60 Gy, delivered over 6 weeks. PROMs were available for review for 607/629 (97%) OTVs: full 433/629 (69%), partial 174/629 (28%). For 75/100 patients (75%; 95% CI:65%-83%), PROM review resulted in any change in physician-reported burden-score, and for 50/100 patients (50%; 95% CI:40%-60%) any change in patients’ on-treatment management. Rates of burden-score and management-changes were similar between academic and community-based practices (78% vs. 73%; 53% vs. 47%, respectively). For 78/100 patients with Feedback Forms, physicians agreed/strongly agreed that PROMs improved patients’ quality-of-care (91%).</div></div><div><h3>Conclusions</h3><div>PROM review changes radiation oncologists’ on-treatment toxicity assessment in 75% and care delivery in 50% of their patients.</div></div>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":"203 ","pages":"Article 110688"},"PeriodicalIF":4.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142871810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development and validation of a nomogram to predict overall survival in patients with External auditory canal cancer 预测外耳道癌患者总生存期的nomogram发展与验证。
IF 4.9 1区 医学
Radiotherapy and Oncology Pub Date : 2025-02-01 DOI: 10.1016/j.radonc.2024.110691
Shaoqiu Zhang , Li Yan , Ruichen Li , Yang Zhao , Xiaoshen Wang , Ye Zhang , Yi Zhu
{"title":"Development and validation of a nomogram to predict overall survival in patients with External auditory canal cancer","authors":"Shaoqiu Zhang ,&nbsp;Li Yan ,&nbsp;Ruichen Li ,&nbsp;Yang Zhao ,&nbsp;Xiaoshen Wang ,&nbsp;Ye Zhang ,&nbsp;Yi Zhu","doi":"10.1016/j.radonc.2024.110691","DOIUrl":"10.1016/j.radonc.2024.110691","url":null,"abstract":"<div><h3>Aim</h3><div>We aimed to examine the influence of various prognostic factors on the outcome of external auditory canal (EAC) cancer and create a graphical prediction tool, marking a first in this field, premised on these determinants.</div></div><div><h3>Methods</h3><div>We retrospectively analysed 173 patients with EAC cancer, making this the largest patient cohort in the literature. Survival analysis was performed using the Kaplan-Meier method, and the log-rank test was used to assess the differences between established prognostic variables. The risk factors for overall survival (OS) rates were analysed by univariate and multivariable Cox regression analyses.</div></div><div><h3>Results</h3><div>The cohort demonstrated 2-, 5-, and 10-year progression-free survival (PFS) rates of 86.9%, 72.7%, and 60.1%, respectively. The overall survival (OS) rates for the cohort at 2, 5, and 10-years were 93.6%, 80.6%, and 65.8%, respectively. The key predictors of both OS and PFS were squamous cell carcinoma, T stage, margin status, and radiotherapy. The nomogram showed good predictive accuracy and discriminative ability. Post-radiotherapy follow-up data indicated that the incidence rates of allotriogeustia, saprodontia, xerostomia, difficulty in opening the mouth, and facioplegia were 1.3%, 6.5%, 22.7%, 8.4%, and 3.2%, respectively.</div></div><div><h3>Conclusion</h3><div>Our findings highlight the significance of squamous cell carcinoma, T stage, margin status, and radiotherapy as predictors of OS and PFS. Validation analysis confirmed the applicability of the developed nomogram in predicting individual survival probabilities for patients with EAC cancers, signifying a notable progression in the diagnosis and treatment of EAC cancers.</div></div>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":"203 ","pages":"Article 110691"},"PeriodicalIF":4.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142872757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of local–regional radiotherapy in de novo metastatic nasopharyngeal carcinoma patients receiving chemo-immunotherapy: A multicenter, propensity score matching study 局部放疗对新发转移性鼻咽癌患者化疗免疫治疗的疗效:一项多中心、倾向评分匹配研究。
IF 4.9 1区 医学
Radiotherapy and Oncology Pub Date : 2025-02-01 DOI: 10.1016/j.radonc.2024.110687
Shui-Qing He , Guo-Ying Liu , Ya-Hui Yu , Lin Wang , Guo-Yi Zhang , Ding-Sheng Peng , Wei-Xin Bei , Chun-Lan Chen , Shu-Hui Lv , Ze-Yu Zhao , Ying Huang , Yan-Qun Xiang
{"title":"Efficacy of local–regional radiotherapy in de novo metastatic nasopharyngeal carcinoma patients receiving chemo-immunotherapy: A multicenter, propensity score matching study","authors":"Shui-Qing He ,&nbsp;Guo-Ying Liu ,&nbsp;Ya-Hui Yu ,&nbsp;Lin Wang ,&nbsp;Guo-Yi Zhang ,&nbsp;Ding-Sheng Peng ,&nbsp;Wei-Xin Bei ,&nbsp;Chun-Lan Chen ,&nbsp;Shu-Hui Lv ,&nbsp;Ze-Yu Zhao ,&nbsp;Ying Huang ,&nbsp;Yan-Qun Xiang","doi":"10.1016/j.radonc.2024.110687","DOIUrl":"10.1016/j.radonc.2024.110687","url":null,"abstract":"<div><h3>Background</h3><div>To evaluate the efficacy of local–regional radiotherapy (LRRT) in de novo metastatic nasopharyngeal carcinoma (dm NPC) patients receiving chemo-immunotherapy as first-line treatment and select the beneficiaries from LRRT.</div></div><div><h3>Methods and materials</h3><div>M1-NPC patients receiving platinum-based chemo-immunotherapy with or without LRRT from four centers were included in this study. The propensity score matching (PSM) analysis was employed to balance the baseline characteristics between the LRRT and non-LRRT groups.</div></div><div><h3>Results</h3><div>546 dm NPC patients (140 patients in the non-LRRT group and 406 patients in the LRRT group) were incorporated. Patients receiving LRRT demonstrated significantly improved progression-free survival (3-year PFS rate, 53.2 % vs 31.2 %, p &lt; 0.001). After PSM analysis, there were 244 patients in the LRRT group and 122 patients in the non-LRRT group. Multivariable analysis indicated that LRRT was not an independent prognostic factor in the matched cohort (HR, 1.25, 95 % CI, 0.92–1.69, p = 0.156). Subgroup analysis among the matched cohort showed a significant increase in PFS for patients with oligo metastatic disease (OMD) who received LRRT (3-year PFS rate, 70.6 % vs 49.3 %, p = 0.043). In contrast, no such benefit was observed in patients with poly metastatic disease (PMD, 3-year PFS rate, 35.8 % vs 27.8 %, p = 0.17). Furthermore, LRRT significantly enhanced survival in patients with undetectable EBV DNA<sub>2-6 cycles</sub> (3-year PFS rate, 57.9 % vs. 43.4 %, p = 0.043), whereas no survival improvement was noted in patients with detectable EBV DNA<sub>2-6 cycles</sub> (16.2 % vs. 20.3 %, p = 0.21).</div></div><div><h3>Conclusion</h3><div>LRRT could prolong PFS in M1-NPC patients. OMD and undetectable EBV DNA<sub>2-6 cycles</sub> are potential indicators for selecting beneficiaries from LRRT.</div></div>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":"203 ","pages":"Article 110687"},"PeriodicalIF":4.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142872758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Modulation of the local angiotensin II: Suppression of ferroptosis and radiosensitivity in nasopharyngeal carcinoma via the HIF-1α-HILPDA axis 局部血管紧张素II的调节:通过HIF-1α-HILPDA轴增强鼻咽癌的铁下垂和放射敏感性。
IF 4.9 1区 医学
Radiotherapy and Oncology Pub Date : 2025-02-01 DOI: 10.1016/j.radonc.2024.110686
Xiuting Huang , Kehai Lin , Weirui Chen , Donghui Zhang , Muhammad Khan , Xiaoxin Ye , Baiyao Wang , Chengcong Chen , Yunhong Tian , Yawei Yuan , Jie Lin
{"title":"Modulation of the local angiotensin II: Suppression of ferroptosis and radiosensitivity in nasopharyngeal carcinoma via the HIF-1α-HILPDA axis","authors":"Xiuting Huang ,&nbsp;Kehai Lin ,&nbsp;Weirui Chen ,&nbsp;Donghui Zhang ,&nbsp;Muhammad Khan ,&nbsp;Xiaoxin Ye ,&nbsp;Baiyao Wang ,&nbsp;Chengcong Chen ,&nbsp;Yunhong Tian ,&nbsp;Yawei Yuan ,&nbsp;Jie Lin","doi":"10.1016/j.radonc.2024.110686","DOIUrl":"10.1016/j.radonc.2024.110686","url":null,"abstract":"<div><h3>Purpose</h3><div>Radiotherapy presents a curative approach for nasopharyngeal carcinoma (NPC); however, the cellular radiosensitivity heterogeneity limits its efficacy. Thus, investigating the specific mechanisms of radioresistance in NPC is crucial for identifying and employing effective radiosensitizing agents to enhance treatment success.</div></div><div><h3>Methods and Materials</h3><div>Radioresistant NPC cell lines HONE1-RR and SUNE1-RR were established. Quantitative reverse transcription-PCR (qRT-PCR), western blot, and enzyme-linked immuno sorbent assay (ELISA) were employed to detect the activation of the angiotensinogen (AGT) and local angiotensin II (Ang II). Transmission electron microscopy, ferrous ion detection, and lipid oxidation levels were utilized to detect radiation-induced ferroptosis in NPC. Bioinformatics analysis, along with qRT-PCR, western blotting, co-immunoprecipitation, and dual-luciferase assays were employed to explore downstream mechanisms. Colony formation assay, Cell Counting Kit-8 (CCK-8) assay, and a nude mouse xenograft model were utilized to assess NPC radiosensitivity. The expression of AGT, hypoxia-inducible factor-1 alpha (HIF-1α), hypoxia-inducible lipid droplet-associated protein (HILPDA), and glutathione peroxidase 4 (GPX4) in NPC tissues was detected through immunohistochemistry.</div></div><div><h3>Results</h3><div>Activation of local Ang II was revealed to play a critical role in driving radioresistance in NPC cells modulating ferroptosis. This local Ang II established a positive feedback loop with HIF-1α through two parallel pathways; Ang II stabilizes HIF-1α by activating the MAPK pathway, and AGT directly binds HIF-1α to prevent its degradation. This AGT-HIF-1α loop regulated NPC cell ferroptosis via transcriptional regulation of HILPDA expression. Moreover, the co-administration of Ang II receptor antagonist (ARB) and ferroptosis inducers markedly increased NPC radiosensitivity.<!--> <!-->Additionally, the expression of AGT, HIF-1α, and HILPDA was closely correlated with the intensity of ferroptosis, radiosensitivity, and prognosis in NPC.</div></div><div><h3>Conclusions</h3><div>Our findings suggest that the AGT-HIF-1α-HILPDA pathway promotes radioresistance in NPC by enhancing lipid droplet accumulation, thereby suppressing ferroptosis. Targeting local Ang II alongside ferroptosis induction offers a promising strategy to improve radiosensitivity in NPC.</div></div>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":"203 ","pages":"Article 110686"},"PeriodicalIF":4.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142872759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The proton RBE and the distal edge effect for acute and late normal tissue damage in vivo 质子RBE和远端边缘效应对体内急性和晚期正常组织损伤的影响。
IF 4.9 1区 医学
Radiotherapy and Oncology Pub Date : 2025-02-01 DOI: 10.1016/j.radonc.2024.110668
Cathrine Bang Overgaard , Fardous Reaz , Christina Ankjærgaard , Claus E. Andersen , Mateusz Sitarz , Per Poulsen , Harald Spejlborg , Jacob G. Johansen , Jens Overgaard , Cai Grau , Niels Bassler , Brita Singers Sørensen
{"title":"The proton RBE and the distal edge effect for acute and late normal tissue damage in vivo","authors":"Cathrine Bang Overgaard ,&nbsp;Fardous Reaz ,&nbsp;Christina Ankjærgaard ,&nbsp;Claus E. Andersen ,&nbsp;Mateusz Sitarz ,&nbsp;Per Poulsen ,&nbsp;Harald Spejlborg ,&nbsp;Jacob G. Johansen ,&nbsp;Jens Overgaard ,&nbsp;Cai Grau ,&nbsp;Niels Bassler ,&nbsp;Brita Singers Sørensen","doi":"10.1016/j.radonc.2024.110668","DOIUrl":"10.1016/j.radonc.2024.110668","url":null,"abstract":"<div><h3>Background and purpose</h3><div>In proton therapy, a relative biological effectiveness (RBE) of 1.1 is used to<!--> <!-->reach an isoeffective biological response between photon and proton doses. However, the RBE varies with biological endpoints and linear energy transfer (LET), two key parameters in radiotherapy. Few <em>in vivo</em> studies have investigated the increasing RBE with increasing LET. This study aims to test the hypothesis that the RBE varies between endpoints and has a distal edge effect <em>in vivo</em>.</div></div><div><h3>Materials and methods</h3><div>Unanesthetized mice<!--> <!-->were restrained<!--> <!-->in jigs where their right hind legs were irradiated with a single dose of protons at the center (LET, <sub>all</sub> = 5.3 keV/μm) and distal edge (LET, <sub>all</sub> = 7.6 keV/μm) of a spread-out Bragg peak (SOBP). 6 MV photons were used as reference. The acute damage and skin toxicity were scored daily until day 30, and the late damage was evaluated using a joint contracture assay for one year after treatment.</div></div><div><h3>Results</h3><div> <!-->An acute damage RBE of 1.06 ± 0.02(1.02–1.10) and late damage RBE of 1.16 ± 0.08(1.00–1.32) were found, displaying an enhanced RBE for late damage in the center SOBP. The distal edge RBE for acute and late damage was 1.15 ± 0.02(1.10–1.19) and 1.26 ± 0.09(1.07–1.43), showing a similar center-to-distal edge RBE enhancement of 8 % and 9 % for acute and late damage.</div></div><div><h3>Conclusion</h3><div>The findings demonstrate an increased RBE for late damage than acute damage and the distal edge effect is evident with increased RBE at the distal end of the proton SOBP <em>in vivo</em>.</div></div>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":"203 ","pages":"Article 110668"},"PeriodicalIF":4.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142829755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predictive biomarkers of radiotherapy- related dermatitis, xerostomia, mucositis and dysphagia in head and neck cancer: A systematic review 头颈癌放疗相关皮炎、口干、黏膜炎和吞咽困难的预测性生物标志物:一项系统综述。
IF 4.9 1区 医学
Radiotherapy and Oncology Pub Date : 2025-02-01 DOI: 10.1016/j.radonc.2024.110689
Alexander Koch , Philipp Reinhardt , Olgun Elicin , Daniel M. Aebersold , Daniel H. Schanne
{"title":"Predictive biomarkers of radiotherapy- related dermatitis, xerostomia, mucositis and dysphagia in head and neck cancer: A systematic review","authors":"Alexander Koch ,&nbsp;Philipp Reinhardt ,&nbsp;Olgun Elicin ,&nbsp;Daniel M. Aebersold ,&nbsp;Daniel H. Schanne","doi":"10.1016/j.radonc.2024.110689","DOIUrl":"10.1016/j.radonc.2024.110689","url":null,"abstract":"<div><h3>Background</h3><div>Radiotherapy is essential for treating head and neck cancer but often leads to severe toxicity. Traditional predictors include anatomical location, tumor extent, and dosimetric data. Recently, biomarkers have been explored to better predict and understand toxicity. This review aims to summarize the current literature, assess data quality, and guide future research.</div></div><div><h3>Methods</h3><div>Two reviewers independently screened EMBASE and PubMed for studies published between 2010 and 2023. Endpoints were dermatitis, mucositis, sticky saliva/xerostomia, and dysphagia. Statistical analysis was performed using R, and bias assessed via a modified QUIPS questionnaire. Pathway analysis was conducted using gProfiler. The study adhered to PRISMA and COSMOS-E guidelines and was registered in the PROSPERO database (#CRD42023361245).</div></div><div><h3>Results</h3><div>Of 2,550 abstracts, 69 publications met the inclusion criteria. These studies involved a median of 81 patients, primarily male (75 %), with common primary tumors in the nasopharynx (32 %) and oropharynx (27 %). Most patients (84 %) had advanced disease (stage III/IV). The most frequently studied biomarkers were DNA-based single-nucleotide polymorphisms (SNPs, 59 %), salivary proteins (13 %), and bacteria (10 %). Ten statistically-significant biomarkers (all SNPs) in low-bias publications were identified, particularly in DNA repair and cell detoxification pathways. Data quality was often poor and few validation studies were present in the dataset.</div></div><div><h3>Conclusion</h3><div>This review provides an overview of the research landscape, highlights research gaps and provides recommendations for future research directions. We identified several potential biomarkers, particularly in DNA repair pathways, that align with current understanding of radiation-induced cell damage. However, the overall data quality was poor, with key clinical variables often missing. Overall, rigorous standardization of reporting, validation studies and multi-center collaborations to increase study power and sample sizes are necessary to build high-level evidence for clinical application.</div></div>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":"203 ","pages":"Article 110689"},"PeriodicalIF":4.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142872760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Aims+Scope/Editorial Board/ Publication information
IF 4.9 1区 医学
Radiotherapy and Oncology Pub Date : 2025-02-01 DOI: 10.1016/S0167-8140(25)00025-8
{"title":"Aims+Scope/Editorial Board/ Publication information","authors":"","doi":"10.1016/S0167-8140(25)00025-8","DOIUrl":"10.1016/S0167-8140(25)00025-8","url":null,"abstract":"","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":"203 ","pages":"Article 110730"},"PeriodicalIF":4.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143132449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prolonged interval hypofractionated radiotherapy facilitates better antitumor immunity 延长间隔低分割放疗有利于更好的抗肿瘤免疫。
IF 4.9 1区 医学
Radiotherapy and Oncology Pub Date : 2025-02-01 DOI: 10.1016/j.radonc.2024.110664
Jie Xiao , Shilong Shao , Yue Deng , Dan Wang , Yi Liu , Shanshan He , Yue Zhao , Wenjun Liao , Jun Zhang , Mu Yang , Shichuan Zhang
{"title":"Prolonged interval hypofractionated radiotherapy facilitates better antitumor immunity","authors":"Jie Xiao ,&nbsp;Shilong Shao ,&nbsp;Yue Deng ,&nbsp;Dan Wang ,&nbsp;Yi Liu ,&nbsp;Shanshan He ,&nbsp;Yue Zhao ,&nbsp;Wenjun Liao ,&nbsp;Jun Zhang ,&nbsp;Mu Yang ,&nbsp;Shichuan Zhang","doi":"10.1016/j.radonc.2024.110664","DOIUrl":"10.1016/j.radonc.2024.110664","url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate the impact of hypofractionated radiotherapy (Hypo-RT) with different interfraction intervals on tumor growth, immune response, and synergistic effects with anti-PD-1 immunotherapy.</div></div><div><h3>Methods</h3><div>The mouse MC38 colon cancer model was utilized. Various radiation regimens were designed to investigate the effects of fraction interval and fraction size on tumor growth, immune mobilization, and combination effects with anti-PD-1 immunotherapy.</div></div><div><h3>Results</h3><div>For a fixed-dose experiment, the 6 × 5 Gy for every other day (qod) regimen demonstrated an equivalent effect on tumor growth compared to the 6 × 5 Gy once daily (qd) regimen, while the 6 × 5 Gy for twice weekly (biw) regimen failed to inhibit tumor growth. Both qod and biw regimens induced an enhanced immune response, unlike the qd regimen. For a fixed biologically equivalent dose experiment, 6 × 5 Gy qod, 4 × 7 Gy biw, and 2 × 11 Gy once weekly (qw) regimens exhibited similar tumor suppression to the 12 × 3 Gy qd regimen. The long-interval Hypo-RT regimens significantly mobilized host immunity, whereas 12 × 3 Gy qd did not. The peripheral and intratumoral T cells increased as the fraction interval and size increased. All Hypo-RT regimens combined with anti-PD-1 immunotherapy demonstrated higher intratumoral CD8 + T cells and more effective tumor growth delay compared to the 12 × 3 Gy qd regime.</div></div><div><h3>Conclusions</h3><div>The current study suggested that a prolonged inter-fraction interval with an increased fraction size in Hypo-RT may be a promising option to balance the therapeutic effect on tumor and immune activation.</div></div>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":"203 ","pages":"Article 110664"},"PeriodicalIF":4.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142795088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The prognostic significance of sarcopenia in patients treated with definitive radiotherapy: A systematic review 接受明确放疗的患者肌肉减少症的预后意义:一项系统综述。
IF 4.9 1区 医学
Radiotherapy and Oncology Pub Date : 2025-02-01 DOI: 10.1016/j.radonc.2024.110663
Alexander J. Vickers , Dónal M. McSweeney , Ananya Choudhury , Jamie Weaver , Gareth Price , Alan McWilliam
{"title":"The prognostic significance of sarcopenia in patients treated with definitive radiotherapy: A systematic review","authors":"Alexander J. Vickers ,&nbsp;Dónal M. McSweeney ,&nbsp;Ananya Choudhury ,&nbsp;Jamie Weaver ,&nbsp;Gareth Price ,&nbsp;Alan McWilliam","doi":"10.1016/j.radonc.2024.110663","DOIUrl":"10.1016/j.radonc.2024.110663","url":null,"abstract":"<div><div>Sarcopenia describes the degenerative loss of muscle mass and strength, and is emerging as a pan-cancer prognostic biomarker. It is linked with increased treatment toxicity, decreased survival and significant healthcare financial burden. Systematic analyses of sarcopenia studies have focused on outcomes in patients treated surgically or with systemic therapies. There are few publications concerning patients treated with radiotherapy. This manuscript presents a pan-cancer systematic review of the association between sarcopenia and survival outcomes in patients treated with definitive (chemo-)radiotherapy. A literature search was performed, with 26 studies identified, including a total of 5,784 patients. The prognostic significance of sarcopenia was mixed. This may reflect lack of consensus in methods used to measure skeletal muscle mass and define sarcopenia. Many papers analyse small samples and present sarcopenia cutoffs optimised on the local population, which may not generalise to external populations. Recent advances in artificial intelligence allow for automatic measurement of body composition by segmenting the muscle compartment on routinely collected imaging. This provides opportunity for standardisation of measurement methods and definitions across populations. Adopting sarcopenia diagnosis into clinical workflows could reduce futile treatments and associated financial burden, by reducing treatment toxicities, and improving treatment completion, patient survival, and quality-of-life after cancer.</div></div>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":"203 ","pages":"Article 110663"},"PeriodicalIF":4.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142795089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信